ストックスクリーナーアプリを入手
3.82
0.26%
0.010
アフターアワーズ：
3.84
0.02
+0.52%
前日終値:
$3.81
開ける：
$3.8
24時間の取引高:
362.24K
Relative Volume:
1.45
時価総額：
$252.40M
収益：
$7.69M
当期純損益:
$-17.65M
株価収益率:
-10.21
EPS:
-0.3743
ネットキャッシュフロー:
$-15.72M
1週間 パフォーマンス:
-4.50%
1か月 パフォーマンス:
-7.51%
6か月 パフォーマンス:
+113.41%
1年 パフォーマンス:
+138.75%
1日の値動き範囲:
$3.80
$3.955
1週間の範囲:
$3.53
$4.0498
52週間の値動き範囲:
$1.30
$4.75
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.82 | 251.74M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Guggenheim | Buy |
| 2025-08-06 | 開始されました | Leerink Partners | Outperform |
| 2025-01-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 開始されました | China Renaissance | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Adagene Inc Adr (ADAG) 最新ニュース
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks
Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India
Adagene reports 31% response rate in colorectal cancer trial - investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - Stock Titan
Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan
Empowering Investor Success - Morningstar
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6% - MarketBeat
ETFs Investing in Adagene, Inc. Sponsored ADR Stocks - tradingview.com
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
AirBoss of America (OTCMKTS:ABSSF) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Alibaba Group (NYSE:BABA) Stock Price Down 2% on Analyst Downgrade - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Adagene (NASDAQ:ADAG) Raised to Hold at Wall Street Zen - MarketBeat
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - wahanariau.com
Adagene Inc. (NASDAQ: ADAG) insider reports 2.39M shares, 5.1% stake - Stock Titan
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Adagene Inc. (ADAG) CEO Peter Luo reports options, RSUs and shares in Form 3 - Stock Titan
Adagene (ADAG) HR executive Form 3 details options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
Adagene Inc. (ADAG) director lists time and performance stock options - Stock Titan
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Bitget
Adagene Inc Adr (ADAG) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):